Sarepta Therapeutics
Gene therapy maker selling ELEVIDYS and PMO drugs for Duchenne muscular dystrophy.
On the record
Checkpoint: Dyne Therapeutics DYNE-251 PDUFA decision for exon-51 DMD, competing with Exondys 51
The call
Sarepta still leads DMD treatment with approved drugs and Roche's backing, but three ELEVIDYS deaths, an EU rejection, and rival gene therapies coming through 2026-2027 leave its lead exposed.
Sarepta makes four FDA-approved drugs for a rare muscle disease called DMD, bringing in about $1.86 billion per year. But in 2025, three patients died after receiving its main new therapy ELEVIDYS, which forced the company to add a serious warning label, cut its staff by more than a third, and lower its 2026 revenue forecast from $1.86B to $1.2-1.4B. The company has real advantages: FDA approval, specialized manufacturing, and a partnership with the giant drugmaker Roche. However, these advantages are being challenged by at least three competitor companies working on similar DMD treatments, including Dyne Therapeutics, which is expected to get FDA approval for its own DMD drug in January 2027 and could take sales from Sarepta's older pill-based treatment. The key question is whether Dyne's new competitor drug will be seen as safer or more effective, which would carve into Sarepta's existing customer base.
Why
01
AI pressure: None apparent. AI tools may speed internal drug discovery, but FDA approval, AAV manufacturing, and patient access are not things a model can replace. Could AI do the core job? Unlikely.
02
Bigger players: None apparent. The real competitors chasing the same exon-51 patients are smaller biotechs like Dyne, REGENXBIO, Solid, and Wave, not larger companies. Could a giant copy it? Probably.
03
What protects it. FDA-approved manufacturing, four approved DMD drugs, patient registries, and Roche's global distribution deal for ELEVIDYS.
What would change this call
FDA decision on Dyne Therapeutics DYNE-251 by PDUFA date Jan 21, 2027. Approval with cleaner safety data would let Dyne take exon-51 patients from Exondys 51.
ENDEAVOR Cohort 8 sirolimus pretreatment data readout. Safe results could restore non-ambulatory ELEVIDYS access lost after 2025 deaths.
Outcome of Roche's new global Phase 3 Elevidys trial for EU resubmission. Success or failure decides whether Sarepta regains European market access ceded after CHMP rejection.
ENDEAVOR Cohort 8 sirolimus pretreatment data readout. Safe results could restore non-ambulatory ELEVIDYS access lost after 2025 deaths.
Outcome of Roche's new global Phase 3 Elevidys trial for EU resubmission. Success or failure decides whether Sarepta regains European market access ceded after CHMP rejection.
Key numbers
- FY2025 net product revenue: $1.864B
- ELEVIDYS 2025 revenue: $898.7M, down from prior guidance
- 2026 revenue guidance cut to $1.2B-$1.4B
Named risks
- Three ELEVIDYS patient deaths from acute liver failure led to FDA black-box warning in 2025.
- Securities fraud class action pending (S.D.N.Y. case 1:25-cv-05317) over safety disclosures.
- 2026 revenue guidance cut roughly 30% versus 2025 amid competitive and regulatory pressure.
- Dyne, REGENXBIO, and Solid advancing rival DMD therapies with 2026-2027 regulatory milestones.
- CEO Doug Ingram's planned retirement by end of 2026 creates leadership transition uncertainty.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Dyne Therapeutics | gaining on | DYNE-251 got FDA priority review, PDUFA Jan 21, 2027, targeting same exon-51 population as Exondys 51 |
| REGENXBIO | gaining on | RGX-202 gene therapy filing expected mid-2026, per Feb 2026 report |
| Solid Biosciences | contesting | SGT-003 in Phase 1/2 as of early 2026, advancing rival DMD gene therapy |
| EU regulators/CHMP | losing to | ELEVIDYS marketing application rejected in EU in 2025, forcing new Phase 3 trial (Apr 2026) |
Questions people ask
- Is Sarepta Therapeutics profitable in 2026?
- No. Sarepta guided 2026 net product revenue to just $1.2B-$1.4B, down from $1.864B in 2025, after a safety crisis cut ELEVIDYS sales; a GAAP net loss was reported for 2025 despite $1.86B revenue.
- Did Sarepta Therapeutics have layoffs?
- Yes. In July 2025 Sarepta cut about 493 confirmed jobs, roughly 36% of staff, to save an estimated $400M annually starting 2026, shrinking headcount from 1,372 (end 2024) to about 835 by July 2026.
- Is Sarepta's ELEVIDYS gene therapy safe?
- It carries serious risk. Three patients died of acute liver failure in 2025, prompting a July 2025 FDA black-box warning and removal of the non-ambulatory indication; a new sirolimus-pretreatment cohort is testing whether access can be safely restored.
- Who is Sarepta Therapeutics' biggest competitor?
- Dyne Therapeutics is the most direct threat: its DYNE-251 has FDA priority review with a PDUFA date of January 21, 2027, targeting the same exon-51 Duchenne population as Sarepta's $965.6M-a-year Exondys 51 (2025 revenue).
- Who owns Sarepta Therapeutics?
- Sarepta is a publicly traded Nasdaq company (SRPT) with no parent; market cap was about $1.67-1.68B as of July 23, 2026. Roche has held its ex-US ELEVIDYS commercialization rights since a December 2019 licensing deal.
- Could AI replace Sarepta Therapeutics?
- Unlikely. Sarepta's value rests on FDA biologics licenses for four approved DMD drugs, AAV/oligonucleotide manufacturing know-how, and its Roche distribution partnership, none of which AI models can replicate or absorb as of this brief (2026-07-24).
Timeline
- 2026-07-22Headcount reported at approximately 835 employees, down from 1,372 in 2024
- 2026-06-30FDA accepts sNDAs for AMONDYS 45 and VYONDYS 53 full approval; PDUFA Feb 28, 2027
- 2026-05-07Q1 2026 net product revenue reported at $330.5M, down sharply year over year
- 2026-04-16Roche starts new global Phase 3 ELEVIDYS trial to attempt fresh EU submission
- 2026-02-25ELEVIDYS commercially launched in Japan via Roche/Chugai, triggering $40M milestone
- 2026-01-12Sarepta reports full-year 2025 net product revenue of $1.864 billion
- 2025-07-16Sarepta announces 36% workforce cut and pipeline restructuring
- 2025-07FDA adds black-box warning to ELEVIDYS; non-ambulatory indication removed
- 2025Three ELEVIDYS patient deaths from acute liver failure reported
- 2025EU CHMP rejects ELEVIDYS marketing application
Head to head
Revision history
24 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- EX-99.1 Sarepta Reports Preliminary Fourth Quarter and Full-Year 2025 Net Product Revenues (2026-01-12)
- Sarepta Therapeutics Announces First Quarter 2026 Financial Results (2026-05-07)
- Sarepta Therapeutics (SRPT) Earnings Call Transcripts
- Sarepta Therapeutics announces commercial launch of ELEVIDYS in Japan for DMD treatment (2026-02-25)
- Roche to start new Elevidys study following setback in Europe (2026-04-16)
- Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results (2026-02-26)
- Sarepta Therapeutics: SRPT Stock Price Quote & News (2026-07-22)
- Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks (2025-07-16)
- 493 employees laid off at biopharmaceutical company... (2025-07-31)
- Sarepta Cuts 36% of Workforce, Plans $400M Annual Cost Savings (2025-07-16)
- Delandistrogene moxeparvovec -> Society and culture
- Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45 and VYONDYS 53 (2026-06-30)